Focus 053112.p65

Vol. 19, No. 10 International Federation of Pharmaceutical Wholesalers May 31, 2012
Latin America set for 10% Growth
(Sources: An article written by Mandy Jackson and published by Scrip, and the Deutsche Bank) As an emerging market, Latin America has an attractive growth Latin American pharmaceutical customers are known for rate, according to Deutsche Bank, a major investment bank. Annual brand loyalty, meaning that they prefer brand name drugs and pharmaceutical sales growth has averaged 13% per year for the past branded generics. Publicly-traded pharmaceutical and consumer/ six years in Latin America - five times the growth of developed mar- pharmaceutical companies - CFR Pharmaceuticals in Chile, kets with expected double-digit increases to continue.
Hypermarcas in Brazil and Genomma Labs in Mexico - reported net Most countries in the region should see 10% annual sales sales of US$2.6 billion in 2011 and anticipatedUS$3 billion in 2012.
growth in the pharmaceutical markets between 2011 and 2015 com- Among global big pharmaceutical and specialty pharmaceutical pared to just 0-3% in the US and 1-4% in Western Europe, according companies, which reported regional sales figures in their 2011 earn- to the bank’s research. It is anticipated that Latin America will signifi- ings reports, Latin America accounted for 9% of Sanofi’s revenue cantly contribute to sales growth for multinational corporations with for a total of US$4.2 billion; 12% of Bayer’s or US$2.8 billion; 10% of local manufacturers being well positioned to capitalize on the market Valeant Pharmaceuticals’ revenue or US$255 million; and 7% of expansion. At more than US$60 billion per year, the region presently Allergan’s for a total of US$391 million. US-based Optimer Pharma- accounts for about 7% of global pharmaceutical sales. Latin Ameri- ceuticals has said that Latin America, starting with Brazil, is the next can pharmaceutical sales of US$67 billion in 2011 are expected to targeted market for the oral antibiotic Dificid (fidaxomicin). Earlier in reach as high as US$81 billion in 2013, including US$33 billion in 2013 March, Valeant bought a 19.9% stake in the Brazilian biotech firm sales in Brazil. Mexico, Columbia and Peru, where consumers self- Pele Nova Biotecnologia for less than US$10 million. In late 2011, pay for a substantial portion of their healthcare costs, also are seen the French life science, energy and information technology venture as attractive markets, although Venezuela and Argentina are more capital firm Truffle Capital said it opened an office in São Paulo, difficult due to political tensions and protectionist governments.
Brazil to bring its existing portfolio companies to the country andinvest in local firms.
Japan’s Rx Grew by 5.5% to
US$120 Billion in 2011
The U.S. Retail-Based Clinic Model
(Sources: Article written by Ian Haydock and published by Scrip) (Source: an article written by Antoinette Alexander and and IMS Japan Pharmaceutical Market.) Japan’s total prescription drug market grew by 5.5% to ¥9,534.9 An article recently published in the Journal of the American billion (US$120 billion) in the 12 months to 31 March, the fiscal year Medical Association promoted the merits of the convenient care for most firms in the country and ahead of the 1 April general reim- industry, and outlined significant ways in which retail-based clinics bursement price cut that is set to dampen growth this year.
are playing an important role in today’s U.S. healthcare system by Hospitals of 100 beds or more accounted for the largest single improving access, cost and coordination of care for patients.
sector of the market, making up 39% of the total and growing by 5%.
In looking at access to care, which is exacerbated by the However overall growth in the 2012 calendar first quarter fell to just shortage of primary care physicians and cost of care, the article, over 2% to ¥2,291.5 billion (US$29.2 billion) affected by lower de- written by Christine K. Cassel, M.D., with the American Board of mand in the run-up to the biennial price cut according to IMS Japan.
Internal Medicine in Philadelphia, stated that retail-based health The aggregate sales of Japan’s top 15 domestic pharmaceuti- clinics provide a solution as they can provide patients with timely, cal firms in the fiscal year fell by around 1%, according to a recent convenient and cost-effective access to care. The article also survey by the main local industry association, the JPMA, suggest- pointed to a third significant challenge facing the U.S. healthcare ing that foreign multinationals are driving much of the broader growth.
system today: coordination of care, especially for those patients This is substantiated by the generally strong double-digit sales in- with multiple chronic conditions. “Lack of coordination is thought creases reported by such firms over the past few months, as their to cost the healthcare system billions of dollars. To date, this has portfolios catch up with those in other major markets through new not been a major area of expertise or availability of retail clinics but, launches. But growth this fiscal year will be constrained in general as they consider a role in chronic care, it is coming into focus.
by the biennial price revision, which averaged around 6% across the Indeed, chronic care plans are an increasingly important priority for board. The reimbursement price of some individual products was cut retail health clinics,” the article stated. “With good communication by 25% under rules for the one-off re-pricing of drugs whose sales between multiple specialists, convenient access in evenings and have grown strongly beyond initial official projections.
on weekends, and familiarity with local community resources, the Top Five Therapeutic Categories in Japan (year to 31 March at retail clinic potentially could be an important component of coordi- NHI Prices were: renin-angiotensin system ¥657.8 billion (US$8.38 nation of care aimed at reducing disease exacerbations, unneces- billion) (+5.4%); Antineoplastics ¥631.5 billion (US$8.05 billion) sary hospitalizations and adverse drug interactions,” the article (+5.2%); Lipid-regulating/anti-atheroma ¥447.6 billion (US$5.70 bil- continued. “If this vision were realized, the retail clinic phenom- Copyright 2012 - International Federation of Pharmaceutical Wholesalers, Inc. All Rights Reserved. Number of Pages: 2
May 31, 2012
Japan.(cont.)
lion) (+3.8%); antacids/anti-ulcers/antiflatulents ¥437.2 billion
head of emerging markets commercial operations commented, “We (US$5.57 billion) (+2.5%); anti-diabetes ¥392.5 billion (US$5.00 bil- have to do a better job in Middle East, Turkey and Africa areas, where we see a great potential, and also in other Latin American In terms of individual products, Sanofi’s antiplatelet agent countries where we are not present today, like Peru, Ecuador, Uru- Plavix (clopidogrel) moved into the top five and was the fastest- growing drug in the top 10. Although it was top for the fiscal year,  A draft law in Russia aims to abolish the requirement for for- the calendar first quarter saw Eisai’s Alzheimer’s disease therapy eign firms to conduct local trials as part of the new drug approval Aricept (donepezil) slip down the rankings to third on a 19% sales process. However the ministry of health and social development fall to ¥25.8 billion (US$363 million), due in part by generic ver- has yet to comment on the draft and with a newly appointed gov- sions; Takeda’s antihypertensive Blopress (candesartan) took the ernment and a new health minister, progress may be slow.
top spot for the quarter, despite a continued decline. Aricept suf-  Mylan Labs received final approval from the US FDA its ab-
fered an overall price cut of around 17% in the April revision, mean- breviated new drug application for a generic version of Pfizer’s ing that its sales are set to come under further pressure this year.
Lipitor (atorvastatin). Lipitor had US sales of US$8.1 billion for the According to IMS’ values for distributor-level sales made 12 months ended in March, according to IMS Health.
directly to wholesalers, Takeda was ranked first, while MSD placed  Canadian retailer Shoppers Drug Mart is acquiring 19 retail
as the largest foreign pharmaceutical multinational in Japan in sixth pharmacies and 3 central fill pharmacies from Paragon for approxi-
position overall. The top 10 companies (year to 31March – sales to mately US$75 million in cash. The acquisition will expand Shoppers’ wholesalers) were: Takeda ¥725.6 (US$9.2 billion) (+4.4%); Astellas retail presence in western Canada, expand its service offering to ¥ 671.0 billion (US$8.5 billion) (+6.6%); Daiichi Sankyo ¥501.9 bil- long-term care facilities and will provide a platform for the company’s lion (US$6.4 billion) (0%); Mitsubishi Tanabe Pharma ¥417.4 billion MediSystem Technologies business to enter the British Columbia (US$5.3 billion) (+3.5%); Eisai ¥401.2 billion (US$5.1 billion) (+6.1%); MSD ¥393.0 billion (US$5.0 billion) (+11.0%); Chugai (Roche) ¥392.1  Generic drug maker Sun Pharmaceutical Industries (India)
billion (US$4.9 billion) (-0.1%); Novartis ¥385.7 billion (US$4.8 bil- appointed Israel Makov as its chairman. Makov formerly served as lion) (+6.3%); Pfizer ¥343.2 billion (US$4.4 billion) (+6.8%); GSK president and CEO of Teva from 2002 to 2007.
¥335.0 billion (US$4.3 billion) (+20.8%).
 PPD has named David Simmons as chairman and CEO, effec-
U.S. Retail.(cont.)
tive June 4th. Prior to joining the CRO, Simmons was president and enon could be transformative for a vast number of patients in the general manager of the emerging markets and established products United States.” The article highlighted the importance of other healthcare professionals, including nurse practitioners and phar- The BrandZ Top 100 Most Valuable Global Brands study, macists, as part of an “effective team of care.” which identifies and ranks the world’s most valuable 100 brands by “The retail clinic is a site where first-line roles for advanced an analysis based of financial data combined with consumer mea- practice nurses and pharmacists have already been shown to be sures of brand equity, listed Walmart as the top retailer (and No. 17
effective in managing acute uncomplicated conditions. Pharmacists’ out of all global brands). The study reports that Walmart is meeting skills are underutilized if they are limited to their role in filling pre- the needs of the digitally connected consumer by offering free WiFi scriptions, the so-called behind-the-counter functions. In effective in store, rebalancing its portfolio between online and physical ac- teamwork approaches to chronic illness, exemplified by many mod- tivity and offering mobile customers with no credit the opportunity els of geriatric care, the pharmacist is an active part of the healthcare to order goods directly from their phones and pay when they are team — in both the inpatient and outpatient settings. In a retail clinic with a pharmacy, clinical expertise is expanded by access to  A proposed change to Europe’s biosimilars regulation, allow- the pharmacist and the pharmacy database available in that setting.
ing the EMA to rely on comparability data from reference products This same team, with active physician involvement, could provide sourced outside the European Union, could significantly reduce the nidus [foundation] for better management of more complex the number of clinical trials that companies wishing to market their chronic illnesses,” the article stated.
products in the EU are required to conduct. However, the originator In looking at the future role of the retail clinic, the article stated, biological reference product would still be required to be authorized “There are challenges, but this is happening already. The question in the EU and adequate bridging data provided.
is whether this phenomenon will grow and flourish in the ways (Sources: Drug Store News and Scrip) described here or whether 20th-century attitudes about physicianand hospital dominance in health care will prevent market-basedsolutions to the healthcare access and cost crisis. This model is achallenge to medical and hospital leadership, as well as to leaders inthe retail health clinic industry, as they pursue the potential oppor- SHOWCASE YOUR ORGANIZATION!
tunities and benefits for the American people.” Become an Exhibitor or Sponsor for IFPW’s 2012 GENERAL MEMBERSHIP MEETING
For more information opportunities, or to register, please visit Takeda will acquire Multilab Indústria e Comércio de
www.ifpw.com/meetings/2012gmm
Produtos Farmacêuticos (Multilab) in Brazil for up to US$270 mil-
lion (Real540 million), expanding its reach in an important emerging market and also into Brazil’s branded generics segment. Takeda’s

Source: http://ifpw.com/documents/FOCUS2012/Focus053112.pdf